**Supplementary Table 5. Inflammatory marker values across cancer types.** Unadjusted mortality, median inflammatory marker values with interquartile ranges, and categorically distributed inflammatory marker values shown for primary tumor site categories of the whole dataset (n=1,071).

Tumor Site	Unadjusted Mortality	NLR (median, IQR)	PLR (median, IQR)	OIS (median, IQR)	mGPS (0/1/2, %)	PI (0/1/2, %)
Head & Neck	38.2%	7.1	390.4	39.8	5/6/11	5/21/3
		(10.8)	(245.0)	(9.2)	(22.7%/27.3%/50.0%)	(17.2%/72.4%/10.3%)
Lung & Thoracic	47.4%	7.8	296.3	37.8	21/23/38	13/86/26
		(9.4)	(249.3)	(9.7)	(25.6%/28.0%/46.3%)	(10.4%/68.8%/20.8%)
Gastroesophageal	32.7%	8.2	238.0	38.4	8/5/18	7/19/10
		(12.5)	(415.4)	(10.6)	(25.8%/16.1%/58.1%)	(19.4%/52.8%/27.8%)
Hepatobiliary	47.3%	6.4	212.5	33.8	13/5/18	12/25/10
		(8.3)	(265.6)	(10.8)	(36.1%/13.9%/50.0%)	(25.5%/53.2%/21.3%)
Duodenal & Lower	38.6%	6.3	309.7	36.5	18/16/42	16/62/13
GI Tract		(9.2)	(221.3)	(10.5)	(23.7%/21.1%/55.3%)	(17.6%/68.1%/14.3%)
Breast	20.9%	4.3	221.7	39.8	36/37/33	33/89/14
		(5.9)	(202.3)	(8.4)	(34.0%/34.9%/31.1%)	(24.3%/65.4%/10.3%)
Gynecological	36.8%	4.9	282.6	36.7	5/9/24	5/35/8
		(5.9)	(273.6)	(10.3)	(13.2%/23.7%/63.2%)	(10.4%/72.9%/16.7%)
Genitourinary	34.3%	6.6	271.9	38.0	26/51/78	18/123/29
		(10.7)	(266.0)	(8.7)	(16.8%/32.9%/50.3%)	(10.6%/72.4%/17.1%)
Skin	39.5%	6.1	217.5	42.5	3/20/11	1/26/8
		(9.0)	(276.6)	(15.0)	(8.8%/58.8%/32.4%)	(2.9%/74.3%/22.9%)
Lymphoma	33.3%	4.8	214.8	40.0	22/14/21	20/32/8
		(5.8)	(335.5)	(11.1)	(38.6%/24.6%/36.8%)	(33.3%/53.3%/13.3%)
Other	26.6%	5.6	255.5	39.1	12/10/13	12/28/11
		(9.4)	(284.9)	(10.6)	(34.3%/28.6%/37.1%)	(23.5%/54.9%/21.6%)

NLR: Neutrophil-lymphocyte ratio; PLR: Platelet-lymphocyte ratio; OIS: OnCovid Inflammatory Score; mGPS: Modified Glasgow prognostic score; PI: Prognostic index; IQR: Interquartile range; GI: Gastrointestinal